viewVentriPoint Diagnostics Ltd.

Ventripoint Diagnostics makes major change to VMS+3.0 as new look company starts trading again

Ventripoint Diagnostics (CVE:VPT-OTC: VPDTF) CEO George Adams joined Steve Darling from Proactive with news the company has made a major change improving their VMS+3.0 diagnostic system that allows physicians to have a 3D model of the heart. This becoming important especially during the COVID-19 pandemic and it's relation to the cardiovascular system.

Adams discusses the major change the machine has undergone and also about the restructuring of the company and how they are back trading in the markets.

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.085 CAD

Market: TSX-V
Market Cap: $5.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...


Ventripoint Diagnostics new Director sees strong path forward updated VMS system

Ventripoint Diagnostics (CVE: VPT-OTC: VPTDF) New Director Hugh MacNaught joined Steve Darling from Proactive to discuss his new role on the board of the company. He also shares his background and what he brings to the company. MacNaught also shared details about the news VMS technology and...

on 15/10/20

2 min read